SQZB (SQZ Biotechnologies Co) EBITDA: $-49.20 Mil (TTM As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SQZB SQZ Biotechnologies Co SQZB
12 GF Score
Price $0.02
View Full Analysis

What is SQZ Biotechnologies Co EBITDA?

SQZ Biotechnologies Co SQZB 12 EBITDA is $-49.20 Mil as of Sep. 2023. GuruFocus rates SQZB with a GF Score™ of 12/100.

SQZ Biotechnologies Co's EBITDA for the three months ended in Sep. 2023 was $-13.35 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-49.20 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

SQZ Biotechnologies Co's EBITDA per Share for the three months ended in Sep. 2023 was $-0.45. Its EBITDA per share for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.67.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

SQZ Biotechnologies Co  (OTCPK:SQZB) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


SQZ Biotechnologies Co EBITDA Related Terms


SQZ Biotechnologies Co EBITDA Historical Data

* Premium members only.

The historical data trend for SQZ Biotechnologies Co's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SQZ Biotechnologies Co EBITDA Chart

SQZ Biotechnologies Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
EBITDA
-18.12 -29.91 -40.12 -57.74 -64.14

SQZ Biotechnologies Co Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.25 -5.78 -15.20 -14.87 -13.35

SQZB vs AGTX, ISCO, VYNT: EBITDA Comparison

For the Biotechnology subindustry, SQZ Biotechnologies Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SQZ Biotechnologies Co EV-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SQZ Biotechnologies Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where SQZ Biotechnologies Co's EV-to-EBITDA falls into.


SQZB
12GF Score
SQZ Biotechnologies Co SQZB
EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

SQZ Biotechnologies Co's EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

SQZ Biotechnologies Co's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2022, SQZ Biotechnologies Co's EBITDA was $-64.14 Mil.

SQZ Biotechnologies Co's EBITDA for the quarter that ended in Sep. 2023 is calculated as

SQZ Biotechnologies Co's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Sep. 2023, SQZ Biotechnologies Co's EBITDA was $-13.35 Mil.

EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-49.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of $-49.20 Mil mean?
SQZ Biotechnologies Co (SQZB) has a EBITDA of $-49.20 Mil as of Sep. 2023. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on SQZ Biotechnologies Co.
Is SQZ Biotechnologies Co's EBITDA too high?
SQZ Biotechnologies Co's current EBITDA is $-49.20 Mil. Overall, SQZ Biotechnologies Co has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SQZ Biotechnologies Co's EBITDA compare to AGTX and ISCO?
SQZ Biotechnologies Co's EBITDA of $-49.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Biotechnology company?
A good EBITDA depends on the Biotechnology industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on SQZ Biotechnologies Co. SQZ Biotechnologies Co's current EBITDA is $-49.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SQZ Biotechnologies Co stock overvalued right now?
SQZ Biotechnologies Co (SQZB) has a current EBITDA of $-49.20 Mil. The current EBITDA is $-49.20 Mil. SQZ Biotechnologies Co's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For SQZ Biotechnologies Co (SQZB), the current EBITDA is $-49.20 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SQZ Biotechnologies Co Business Description

Address 200 Arsenal Yards Boulevard, Suite 210, Watertown, MA, USA, 02472
SQZ Biotechnologies Co is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ has the ability to deliver multiple materials into many patient cell types to engineer what it believes to be an unprecedented range of potential therapeutics for a range of diseases. The company has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients and potentially improve the patient experience over existing cell therapy approaches, with accelerated production timelines under 24 hours and the elimination of preconditioning and lengthy hospital stays.
12GF Score

Get the complete analysis for SQZB

EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price